| Literature DB >> 31023246 |
Nobuhiro Asai1,2, Hiroyuki Suematsu2, Atsuko Yamada2, Hiroki Watanabe1,2, Naoya Nishiyama1,2, Daisuke Sakanashi2, Hideo Kato2, Arufumi Shiota2, Mao Hagihara2, Yusuke Koizumi1,2, Yuka Yamagishi1,2, Hiroshige Mikamo3,4.
Abstract
BACKGROUND: Brevibacteria are obligate aerobic gram-positive rods that are associated with milk products and are also found on human skin. Brevibacterium has been reported as a rare cause of catheter related blood steam infection mainly in immunocompromised hosts such as malignancies or AIDS patients. CASEEntities:
Keywords: Bacteremia; Brevibacterium paucivorans; Compromised host; Immunocompetent
Mesh:
Substances:
Year: 2019 PMID: 31023246 PMCID: PMC6485150 DOI: 10.1186/s12879-019-3962-y
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Fig. 1showed (a) blood culture Gram staining and (b) Brevibacterium paucinovorans colony morphology on trypticase soy agar II containing 5% sheep blood
Fig. 2showed that both the organism, B. paucivorans and JCM 11567T had a lack of hydrolysis of casein, while JCM 2594T showed a hydrolysis of casein
Antimicrobial susceptibility of Brevibacterium paucivorans isolated from blood culture
| Antimicrobial agents | MIC (μg/mL) | Interpretation |
|---|---|---|
| Ampicillin | > 0.5 | |
| Gentamicin | 1 | S |
| Amikacin | 8 | |
| Ceftazidime | <=1 | |
| Ceftriaxone | 2 | I |
| Cefazolin | 4 | |
| Cefepime | 2 | I |
| Clindamycin | > 4 | R |
| Ciprofloxacin | 0.25 | S |
| Imipenem | <=0.5 | S |
| Levofloxacin | <=0.25 | |
| Rifampicin | <=0.12 | S |
| Vancomycin | <=0.5 | S |
| Daptomycin | 0.5 | S |
| Meropenem | <=0.5 | S |
| Doxycycline | <=0.5 | S |
MIC minimum inhibitory concentration, S susceptible, I intermediate, R resistant
Previous reports about Brevibacterium species bacteremia
| Author (Year) | Sex | Age | Underlying disease | Indwelling catheter | Treatment regimen | Outcome | |
|---|---|---|---|---|---|---|---|
| McCaughey (1991) [ | M | 40 |
| Zollinger-Ellison syndrome | + | EM | Improved |
| Lina (1994) | M | 19 | Not specified | Lymphoblastic lymphoma | + | TEIC AMK | Recurred |
| Reinert (1995) [ | M | 25 |
| Testicular chorion carcinoma | + | PIPC | Recurred |
| Kaukoranta-Tolvanen (1995) [ | F | 46 |
| Non-Hodgkin Lymphoma | + | ND | Recurred |
| Castagnola (1997) [ |
| Neuro-blastoma | + | ND | Improved | ||
| Brazzola (2000) [ | F | 18 |
| AIDS | + | CPFX | Improved |
| Ogunc (2002) [ | ND | 60 | Not specified | Chronic lymphatic leukemia | ND | CAZ | Improved |
| Janda (2003) [ | M | 34 |
| AIDS | + | VCM | Improved |
| Beukinga (2004) [ | F | 43 |
| Crohn’s disease | + | VCM | Dead |
| Beukinga (2004) [ | M | 31 |
| Received HD. | + | VCM | Improved |
| Ulrich (2006) [ | F | 62 |
| Pulmonary hypertension | + | VCM followed by MFLX | Improved |
| Ours (2018) | F | 94 |
| Diabetes mellitus | – | MEPM | Improveda |
M male, F female, ND not described, AIDS acquired immunodeficiency syndrome, EM erythromycin, TEIC teicoplanin, AMK amikacin, PIPC piperacillin, CPFX ciplofloxacin, VCM vancomycin, GM gentamicin, MFLX moxifloxacin, MEPM meropenem. aDeath caused others